| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/14/1996 | EP0696593A2 Inhibitors of farnesyl protein transferase |
| 02/14/1996 | EP0696578A2 Polyamines and polypeptides useful as antagonists of excitatory amino acid neurotransmitters and/or blockers of calcium channels |
| 02/14/1996 | EP0696456A2 Combination of necrosis inducing substances with substances which are activated by necrosis for the selective treatment of tumours and or inflammatory diseases |
| 02/14/1996 | EP0696455A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs |
| 02/14/1996 | EP0696452A1 Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof |
| 02/14/1996 | EP0696326A1 Methods of treating and detecting cancer using viruses |
| 02/14/1996 | EP0696321A1 Macrophage inflammatory protein variants |
| 02/14/1996 | EP0696320A1 Human n-methyl-d-aspartate receptor subunits, nucleic acids encoding same and uses therefor |
| 02/14/1996 | EP0696318A1 Catalytic antibodies which hydrolyze primary amides and methods for eliciting such antibodies |
| 02/14/1996 | EP0696317A1 HUMAN $i(SYK) |
| 02/14/1996 | EP0696290A1 Bicyclopolyazamacrocyclophosphonic acids, their complexes and conjugates, for use as contrast agents, and processes for their preparation |
| 02/14/1996 | EP0696208A1 Oral drug delivery compositions and methods |
| 02/14/1996 | EP0696206A1 Adenoviruses having modified fiber proteins |
| 02/14/1996 | EP0696205A1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 02/14/1996 | EP0696203A1 Use of ceruletide diethyl amine salt in the treatment of psoriasis |
| 02/14/1996 | EP0696202A1 Pharmaceutical composition containing thymoctonan and azt |
| 02/14/1996 | EP0696201A1 Supplemented and unsupplemented tissue sealants, methods of their production and use |
| 02/14/1996 | EP0696200A1 Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression |
| 02/14/1996 | EP0696199A1 Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
| 02/14/1996 | EP0696198A1 Novel polypeptide having factor xa inhibitory activity |
| 02/14/1996 | EP0205579B1 Methods and compositions useful in the diagnosis and treatment of autoimmune diseases |
| 02/14/1996 | CN1116847A N-(3-piperidinylcarbonyl)-beta-alanine derivatives as PAF antagonists |
| 02/14/1996 | CN1116629A Monomeric insulin analog formulations |
| 02/14/1996 | CN1116628A Cyclopeptides of the formulal |
| 02/14/1996 | CN1116627A New peptides derived from trifluorumethylketones, process for their preparation and the pharmaceutical compositions which contain them |
| 02/14/1996 | CN1116522A Stable freeze-dried formulation comprising a protein assay kit |
| 02/14/1996 | CN1030999C Process for preparation of trypsin inhibitor |
| 02/14/1996 | CN1030988C Crystalline huma proinsulin and process for its production |
| 02/14/1996 | CA2155920A1 Use of interferon for the inhibition of proliferation and differentiation of primitive hematopoietic progenitor cells |
| 02/13/1996 | US5491220 Surface loop structural analogues of fibroblast growth factors |
| 02/13/1996 | US5491217 LHRH antagonists having modified aminoacyl residues at positions 5 and 6 |
| 02/13/1996 | US5491216 Tri-arginine insulins |
| 02/13/1996 | US5491143 Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ACE |
| 02/13/1996 | US5491135 Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals |
| 02/13/1996 | US5491132 Amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same |
| 02/13/1996 | US5491131 Somatostatin-active polypeptide composition |
| 02/13/1996 | US5491130 Peptide inhibitors of fibronectin and related collagen-binding proteins |
| 02/13/1996 | US5491129 Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them |
| 02/13/1996 | US5491128 Aglycons of A/16686 antibiotics |
| 02/13/1996 | US5491088 Genetic engineering |
| 02/13/1996 | US5491082 Plasminogen activator covalently bonded to a porous body of β-tricalcium phosphate |
| 02/13/1996 | US5491075 Culture product |
| 02/13/1996 | US5491073 Cloning of chicken anaemia DNA |
| 02/13/1996 | US5490988 Delivery of therapeutic agents to a target site |
| 02/13/1996 | US5490984 Injecting wound healing agents into defective area |
| 02/13/1996 | US5490981 Diagnostic and therapeutic compositions and methods for lipoprotein(a) |
| 02/13/1996 | US5490980 Transglutaminase crosslinks proteins by catalyzing the active ingrediants to glutamine residues |
| 02/12/1996 | CA2155448A1 Inhibitors of farnesyl protein transferase |
| 02/11/1996 | CA2155629A1 Human interleukin 6 inhibitor |
| 02/09/1996 | CA2155496A1 Nucleic acid-binding oligomers for therapy and diagnosis |
| 02/08/1996 | WO1996003649A1 Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME |
| 02/08/1996 | WO1996003515A2 Surface expression of enzyme in gene directed prodrug therapy |
| 02/08/1996 | WO1996003512A1 Calcium independent cytosolic phospholipase a2/b enzymes |
| 02/08/1996 | WO1996003503A1 Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide |
| 02/08/1996 | WO1996003502A2 Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer |
| 02/08/1996 | WO1996003501A1 Dual hybrid system |
| 02/08/1996 | WO1996003500A1 Sustance with antiviral activity |
| 02/08/1996 | WO1996003499A1 Receptor-ligand assay |
| 02/08/1996 | WO1996003438A1 Antibodies which activate an erythropoietin receptor |
| 02/08/1996 | WO1996003437A1 PTH OR PTHrP ANTAGONISTS |
| 02/08/1996 | WO1996003436A2 EQUINE η-INTERFERON |
| 02/08/1996 | WO1996003435A2 FELINE η-INTERFERON |
| 02/08/1996 | WO1996003434A1 Megakaryocyte differentiation/proliferation factor |
| 02/08/1996 | WO1996003432A1 Novel process for the production of biologically active dimeric protein |
| 02/08/1996 | WO1996003431A1 Improvements relating to cell growth |
| 02/08/1996 | WO1996003430A1 Organic compounds |
| 02/08/1996 | WO1996003429A1 Stable analogs of bioactive peptides containing disulfide linkages |
| 02/08/1996 | WO1996003428A1 Antiprotozoal cyclic tetrapeptides |
| 02/08/1996 | WO1996003426A1 Human serum albumin-porphyrin complexes with the ability to bind oxygen and therapeutic uses thereof |
| 02/08/1996 | WO1996003425A1 Process for folding of proteins like recombinant hirudin or epidermal growth factor |
| 02/08/1996 | WO1996003415A1 Human potassium channel 1 and 2 proteins |
| 02/08/1996 | WO1996003414A1 Antimessenger oligonucleotides and urokinase receptor reversion of the invasive phenotype of transformed human fibroblasts by antimessenger oligonucleotide inhibition of urokinase receptor gene expression |
| 02/08/1996 | WO1996003374A1 Thrombin inhibitors |
| 02/08/1996 | WO1996003152A1 Antisense oligonucleotides against hepatitis b viral replication |
| 02/08/1996 | WO1996003151A2 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 02/08/1996 | WO1996003148A1 Method and drug for treating diabetes |
| 02/08/1996 | WO1996003146A1 Retroviral transduction of cells using soluble complement inhibitors |
| 02/08/1996 | WO1996003143A1 Methods for treating bleeding disorders |
| 02/08/1996 | WO1996003142A1 Drug delivery composition for the nasal administration of antiviral agents |
| 02/08/1996 | WO1996003141A1 Pharmaceutical compositions comprising a chimaeric tnf binding protein |
| 02/08/1996 | WO1996003140A1 HLA binding peptides and their uses |
| 02/08/1996 | WO1996003138A1 Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| 02/08/1996 | WO1996003136A1 Inhibition of platelet binding |
| 02/08/1996 | WO1996003122A2 Use of gabapentin in the treatment of anxiety and panic |
| 02/08/1996 | WO1996003117A1 Incorporation of biologically active molecules into bioactive glasses |
| 02/08/1996 | WO1996003116A1 Controlled release of metal cation-stabilized interferon |
| 02/08/1996 | WO1996003106A2 Allergenic peptides derived from poa pratensis |
| 02/08/1996 | WO1995026983A3 Treatment or diagnosis of abnormal signal transduction disorders |
| 02/08/1996 | WO1995022611A3 Methods and compositions for stimulating bone cells |
| 02/08/1996 | DE4427531A1 Human beta-defensin 1 isolated from haemofiltrate |
| 02/08/1996 | DE4427526A1 Use of spleen peptide(s), beta-human chorionic gonadotropin (HCG) and/or beta-HCG epitope(s) |
| 02/08/1996 | DE4427395A1 New human circulating cytokine CC-1 and related nucleic acid |
| 02/08/1996 | DE4427221A1 Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie Retrovirus-induced osteoclast modulation for osteoporosis therapy |
| 02/08/1996 | DE4427219A1 Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase Nucleic acid for initiation of the activity of RNase H and reverse transcriptase |
| 02/08/1996 | DE4418936A1 Polypeptid Polypeptide |
| 02/08/1996 | CA2196070A1 Antisense oligonucleotides against hepatitis b viral replication |
| 02/08/1996 | CA2196052A1 Intracellular expression of carboxypeptidase g2 in enzyme prodrug therapy |
| 02/08/1996 | CA2196051A1 Surface expression of enzyme in gene directed prodrug therapy |
| 02/08/1996 | CA2195994A1 Controlled release of metal cation-stabilized interferon |
| 02/08/1996 | CA2195868A1 Antibodies which activate an erythropoietin receptor |